2017 American Transplant Congress
Incidence of Cytomegalovirus Infection Among Liver Transplant Recipients Maintained on a Cyclosporine vs. Tacrolimus-Based Immunosuppression Regimen.
The Ohio State University Wexner Medical Center, Columbus, OH
Background: Cytomegalovirus (CMV) is the most common viral pathogen that affects patient outcomes after liver transplant. Potent immunosuppressive agents predispose patients to an increased risk…2016 American Transplant Congress
Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus: A Cost-Effectiveness Analyses.
Nephrology Division, Hospital do Rim - UNIFESP, Sao Paulo, Brazil.
A cost-effectiveness analysis was performed using data from a prospective single center trial where de novo kidney transplant recipients received a single 3 mg/kg dose…2016 American Transplant Congress
Experience of Short-Term Preemptive Treatment for Cytomegalovirus Infection in Seropositive Patients After Liver Transplantation – Ten Years Result of a Single Institution.
Background/purpose Cytomegalovirus (CMV) infection remains a challenge following liver transplantation. Preemptive treatment is an effective strategy for CMV infection. This report shares the ten years'…2016 American Transplant Congress
Infectious Complication in Extremely Elderly Kidney Transplant (KT) Recipients: A Leading Cause of Death.
Introduction: The incidence of infection after KT have been reported to directly increase with recipient's age, likely due to the combined effect of co-morbidities and…2016 American Transplant Congress
Kinetics of Cytomegalovirus Load in Kidney Transplant Recipients Receiving Everolimus or Mycophenolate Sodium and No Pharmacological Prophylaxis.
Hospital do Rim, São Paulo, Brazil.
The purpose of this analysis is to investigate the kinetics of cytomegalovirus (CMV) viral load in kidney transplant recipients receiving tacrolimus (TAC) plus everolimus (EVR)…2016 American Transplant Congress
Standard Dose Valganciclovir Prophylaxis for High-Risk Kidney Transplant Recipients Reduces Incidences of Breakthrough and Resistant Cytomegalovirus Infection.
University of Michigan, Ann Arbor, MI.
Background: Valganciclovir (VGCV) 900 mg/day is the standard dose (SD) for CMV prophylaxis in patients with CrCl > 60 ml/min, although some transplant centers use…2016 American Transplant Congress
Prospective Randomized OPEN Trial Designed to Reduce the Incidence of Cytomegalovirus (CMV) Infection in DE NOVO Kidney Transplant Recipients Two-Year Results.
Transplant, Hospital Geral de Fortaleza, Fortaleza, CE, Brazil.
Introduction: CMV infection is a frequent complication following organ transplantation, and is associated with inferior long-term patient and graft survival. Here we report the results…2016 American Transplant Congress
Initial Evaluation of Use of NAT in Assignment of CMV and EBV Infection Status in Children Awaiting Solid Organ Transplant.
Medicine, University of Alberta, Edmonton, Canada.
Purpose: The presence of passive antibodies, transfusion-acquired or maternal in infants, can make serologic determination of pre-transplant CMV and EBV status in children unreliable. We…2016 American Transplant Congress
Subclinical Cytomegalovirus Viraemia in Renal Transplant Recipients.
Background: Studies suggest low-level cytomegalovirus (CMV) viraemia, detected with sensitive molecular assays, may lead to poorer graft outcomes following renal transplantation.Aims: Investigate the incidence, outcomes,…2016 American Transplant Congress
Sirolimus Regimen and Viral Serology as Risk Factors for Outcomes of Adult Kidney Transplants: 14-Year Cumulative Data in the United States.
Department of Medicine, Univ. of Florida, College of Medicine, Gainesville, FL.
BACKGROUND: The relative risks for patient mortality, graft loss and malignancy in the five years following kidney-only transplant (KT) based on sirolimus (SRL) regimen at…
- « Previous Page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- …
- 33
- Next Page »